In the wake of pa­tient death, Sutro says its Chi­nese part­ner is re­think­ing their deal and with­hold­ing $40M

A lit­tle over two months af­ter bran­dish­ing a Chi­na deal — its first ma­jor pact since team­ing up with Mer­ck in 2018 — fea­tur­ing $40 mil­lion in up­front, Sutro Bio­phar­ma warned in­vestors the mon­ey may not come through any time soon.

The dis­clo­sure came short­ly af­ter Sutro re­leased a new batch of da­ta from a Phase I study, where a pa­tient died fol­low­ing a case of neu­trope­nia — dan­ger­ous­ly low lev­els of a cer­tain white blood cell — deemed re­lat­ed to its drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER